Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Energy stocks weigh down markets
Thu, 24 Jul 11:30 am

After opening weak, the Indian stock markets have remained below the dotted line in morning session. Among the sectoral indices, maximum buying activity is witnessed in Metal and Banking stocks, while Energy and Pharma stocks are at the receiving end.

The BSE-Sensex is trading down 16 points. The NSE-Nifty is trading down 5 points. The BSE Mid Cap index is trading up 0.2% and the BSE Small Cap index is trading up 0.4%. The rupee is trading at 60.02 to the US dollar.

Software stocks are trading mixed today. While HCL technologies is leading the gainers; Tata Consultancy Services (TCS) is leading the losers. India's fifth largest software firm Tech Mahindra, has announced a big expansion plan in Korea. Tech Mahindra had entered the Korean market in May 2002 and has already acquired significant experience across services lines and industries in the country. The company plans to establish partnerships with local universities, business schools and trade bodies over the next three years while creating local employment opportunities. The company aims to grow in various verticals like Manufacturing, Automobile, Aerospace, Defense, Telecom, Oil & Gas, BFSI and Healthcare. It will operate as a local Korean company in partnership with a Korean conglomerate. The Mahindra Group is already among the largest foreign investors in Korea after the purchase of Ssangyong motors by Mahindra & Mahindra. Tech Mahindra is trading up 1.5% today.

Indian pharma stocks are trading mixed today. Panacea Biotech and Dishman Pharma are among the stock leading the gainers while Ipca labs and Natco Pharma are among the stocks leading the losers. As per a financial daily, Ipca has received six 483s from United State Food and Drug Agency (USFDA) on its Ratlam API facility. As of now the company has voluntarily discontinued the shipments of the APIs in the US markets and looking forward to resolve the issue in next 4-6 months. The company's sales and profit might get impacted. USFDA issued the 483s to the firm's management at the conclusion of an inspection when an investigator had observed conditions that in their judgment might constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts in the US. Ipca Labs is trading down by 5.8% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Energy stocks weigh down markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.